Psoriatic Arthritis Market and Forecast Analysis 2035 - Cosentyx will Displace Stelara as the Preferred Biologic in the Post-TNF Setting - ResearchAndMarkets.com

DUBLIN--()--The "Psoriatic Arthritis Market and Forecast Analysis 2035" report has been added to ResearchAndMarkets.com's offering.

Psoriatic arthritis (PsA) is an inflammatory arthropathy associated with psoriasis, which is classified within the group of spondyloarthritis. With the exception of the distal interphalangeal joints (hands and feet), there are no predictable joints for involvement in PsA, and the signs of inflammation are often more difficult to detect than those associated with rheumatoid arthritis. PsA is common in patients with psoriasis, and there is some evidence to suggest that the severity of psoriasis is associated with an increased risk for - although not greater severity of - PsA.

Market Snapshot

  • Cosentyx will displace Stelara as the preferred biologic in the post-TNF setting.
  • Humira is the preferred biologic to treat PsA due to its efficacy in skin and joint symptoms.
  • A modest 6.8% increase in the diagnosed prevalent population of psoriatic arthritis is forecasted during 2017-37.
  • The increasing availability of novel biologic therapies is set to intensify competition in the post-TNF setting.
  • Product differentiation is critical for new biologic and small molecule therapies attempting to enter the market.
  • Biosimilar TNF-alpha inhibitors present the greatest challenge to wider uptake of Cosentyx and Taltz.

Key Topics Covered:

FORECAST: PSORIATIC ARTHRITIS (Published on 16 October 2017)

Overview

Executive Summary

Market Overview And Trends

Market Definition And Methodology

Cimzia (Certolizumab Pegol)

Cosentyx (Secukinumab)

Enbrel (Etanercept)

Humira (Adalimumab)

Orencia (Abatacept)

Otezla (Apremilast)

Remicade (Infliximab)

Simponi (Golimumab)

Stelara (Ustekinumab)

Taltz (Ixekizumab)

Tremfya (Guselkumab)

Xeljanz (Tofacitinib)

TREATMENT: PSORIATIC ARTHRITIS (Published on 16 October 2017)

Overview

Executive Summary

Primary Research Methodology

Disease Definition And Diagnosis

Patient Segmentation

Current Treatment Options

Prescribing Trends

Compliance

Unmet Needs In Psoriatic Arthritis

Future Treatment Trends

Impact Of Biosimilars

EPIDEMIOLOGY: PSORIATIC ARTHRITIS (Published on 24 July 2018)

Overview

Disease Background

Methodology

Forecast

Bibliography

Appendix: Additional Sources

MARKETED DRUGS: PSORIATIC ARTHRITIS (Published on 17 October 2017)

Overview

Executive Summary

Product Overview

Product Profile: Cimzia

Product Profile: Cosentyx

Product Profile: Enbrel

Product Profile: Humira

Product Profile: Orencia

Product Profile: Otezla

Product Profile: Remicade

Product Profile: Siliq

Product Profile: Simponi

Product Profile: Stelara

Product Profile: Taltz

PSORIATIC ARTHRITIS PRICING, REIMBURSEMENT, AND ACCESS (Published on 24 June 2016)

Overview

Executive Summary

Market Context

Global Payer Insights

Us Pricing

Us Payer Insights

Us Reimbursement

Japan

Five Major Eu Markets Pricing

Five Major Eu Markets Payer Insights

Biosimilar Tnf-Alpha Inhibitors In The Five Major Eu Markets

France

Germany

Italy

Spain

Uk

Methodology

PIPELINE: PSORIATIC ARTHRITIS (Published on 17 October 2017)

Overview

Executive Summary

Clinical Pipeline Overview

Additional Pharma Intelligence Pipeline Resources

Product Profile (Late Stage): Tremfya

Product Profile (Late Stage): Xeljanz

Product Profile (Late Stage): Upadacitinib

For more information about this report visit https://www.researchandmarkets.com/r/bdq4xh

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs